#278 ‒ Breast cancer: how to catch, treat, and survive breast cancer | Harold Burstein, M.D., Ph.D.

Episode Summary

Executive Summary: Peter Atiyah and Dr. Harold Bernstein provide a comprehensive overview of breast cancer biology, screening, diagnosis, staging, genetics, and treatment. They emphasize that early detection and subtype-specific therapy have dramatically improved outcomes, while also highlighting the nuanced tradeoffs in managing DCIS/LCIS, the limited role of some preventive drugs, and the importance of multidisciplinary care and genetic counseling.

Main Topics: Breast cancer epidemiology and risk (Priority: 5/5): They review lifetime risk, mortality, and why incidence has risen over time, linking population-level changes in puberty, childbearing, and breastfeeding patterns to higher breast cancer rates in developed societies. Breast anatomy, pathology, and precursor lesions (Priority: 5/5): The discussion explains breast development, ductal/lobular anatomy, and the progression from atypical hyperplasia to DCIS/LCIS and invasive cancer, using colon polyp analogies to clarify pre-cancerous states. Screening and diagnostic workup (Priority: 5/5): They cover self-awareness, mammography, BI-RADS, ultrasound, MRI, and core needle biopsy, stressing that screening finds many benign or pre-cancerous lesions and that tissue diagnosis remains decisive. Breast cancer subtypes and staging (Priority: 5/5): A major framework is the three biologic subtypes—ER+/HER2-, triple negative, and HER2+—plus TNM staging, with prognosis driven by tumor size, nodal status, and tumor biology. Treatment of DCIS and invasive breast cancer (Priority: 5/5): They discuss lumpectomy, mastectomy, sentinel node biopsy, radiation, endocrine therapy, chemotherapy, HER2-targeted therapy, immunotherapy, and neoadjuvant treatment, emphasizing subtype-specific management. Genetics and hereditary risk (Priority: 4/5): The conversation covers BRCA1/2 and other inherited mutations (PALB2, CHEK2, ATM), their autosomal dominant inheritance, and how genetic testing informs surveillance, prophylactic surgery, and family counseling. Multidisciplinary care and male breast cancer (Priority: 3/5): They stress the value of coordinated care among surgery, radiation, pathology, imaging, genetics, and medical oncology, and note that men can develop breast cancer and should not ignore breast/chest changes.

Key Arguments: Breast cancer risk is common at the population level, but most individual risk factors only modestly shift absolute risk. Breast cancer is best understood through biologic subtypes; treatment and prognosis differ substantially by ER, PR, and HER2 status. Screening mammography improves outcomes by shifting diagnosis toward earlier-stage disease, even though it also increases detection of DCIS and LCIS. DCIS is a stage 0 precursor lesion; treatment reduces recurrence but has not clearly been shown to reduce mortality. LCIS is primarily a risk marker rather than a lesion treated like invasive cancer; close surveillance and sometimes endocrine prevention are favored. Tissue pathology is the foundation of management; imaging alone cannot reliably determine the full diagnosis or treatment plan. Genetic testing is increasingly important after diagnosis because hereditary mutations change surveillance, prevention, and family counseling. Modern breast cancer care depends on multidisciplinary coordination and high-quality pathology, imaging, surgery, radiation, and systemic therapy. Neoadjuvant therapy can shrink tumors, reduce surgical morbidity, and provide prognostic information through pathologic complete response. Anti-estrogen therapy is highly effective for invasive ER-positive disease, but its preventive use in DCIS/LCIS often offers only small absolute benefit relative to side effects.

Data Points: Lifetime breast cancer risk: About 1 in 8 women (12% lifetime risk) - Estimated lifetime risk for American women Annual U.S. breast cancer cases: Roughly 275,000 per year - Broad U.S. incidence estimate discussed in the episode Annual U.S. breast cancer deaths: Roughly 38,000 per year - Broad U.S. mortality estimate discussed in the episode Overall cure rate: About 80% to 85% - Approximate proportion of women cured in steady-state U.S. practice ER-positive/HER2-negative share: 70% to 75%+ - Most common breast cancer subtype Triple-negative share: About 10% to 15% - Subtype lacking ER, PR, and HER2 HER2-positive share: About 10% to 15% - Subtype with HER2 amplification Peak incidence age for ER-positive disease: Around age 65 - Population peak for the most common subtype DCIS upstaging rate at surgery: About 15% to 20% - Core-biopsy DCIS later found to have invasive cancer on excision DCIS recurrence without treatment: About 25% to 30% at 10 years in older trials - Lumpectomy alone in historical studies DCIS recurrence with radiation: About 12% to 15% at 10 years in older trials - Radiation roughly halved recurrence risk Additional benefit of tamoxifen after DCIS: Roughly another 50% relative reduction; about 3% to 5% absolute benefit in modern practice - After lumpectomy plus radiation, especially for ER-positive DCIS LCIS/atypia risk estimate: About 0.5% to 1% per year - Approximate annual risk after atypical hyperplasia/LCIS Tamoxifen prevention trial risk: About 13 per 1,000 women per year reduced to 5 to 6 per 1,000 per year - NSABP P1 prevention study in higher-risk women Overall prevention trial absolute risk: About 4% over 5 years reduced to about 2% - Tamoxifen prevention benefit in the P1 study Stage 1 definition: Tumor 2 cm or smaller, node negative - Early-stage breast cancer staging Stage 4 median survival: About 5 years - Metastatic breast cancer overall, varying by subtype Male breast cancer frequency: 1 case for every 200 female cases - Approximate incidence ratio Hereditary mutation contribution: About 8% to 10% of all breast cancers - Proportion linked to specific inherited mutations BRCA1/2 contribution to hereditary cases: About half of hereditary breast cancer - BRCA1 and BRCA2 account for roughly 5% of all breast cancers Genomic testing impact: About two-thirds of women previously offered chemotherapy can now avoid it - ER-positive/HER2-negative disease guided by assays like Oncotype DX

Pivotal Quotes: "The good news is that only a small fraction of those will be fatal." — Dr. Harold Bernstein: On lifetime breast cancer risk versus mortality "DCIS is stage zero breast cancer, or as I like your nomenclature earlier, I call it a colon polyp of breast cancer." — Dr. Harold Bernstein: Explaining ductal carcinoma in situ as a precursor lesion "The quality of pathology is the foundation for all of cancer care." — Dr. Harold Bernstein: On why expert review and multidisciplinary care matter

Implications: Listeners should understand that breast cancer is highly treatable when found early and managed by subtype. For patients, the key is accurate pathology, appropriate screening, and individualized decisions about surgery, radiation, endocrine therapy, and genetics. For systems, multidisciplinary care and better diagnostics remain crucial.